Thyrocare Technologies Limited has informed the Exchange regarding change in Directors of the Company.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies held its Board meeting on May 7, 2026, approving several key matters. The Board recommended a final dividend of Rs. 7 per share for FY 2025-26, bringing the total dividend for the year to Rs. 9.33 per share (post bonus adjustment). The company appointed Price Waterhouse Chartered Accountants LLP as the new statutory auditor for a 5-year term, replacing M S K A & Associates LLP upon completion of their term. Mr. Rahul Franklin Guha was re-appointed as Chairman, MD & CEO for another 5 years. Two directors resigned citing pre-occupation: Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah. Two new directors were appointed: Mr. Uday Patel Kadam and Mr. Gaurav Verma, both associated with API Holdings Limited. The Board also approved an investment of up to Rs. 5.50 crores in Think Health Diagnostics Private Limited (a wholly owned subsidiary) and alterations to the Memorandum of Association to expand the company's objects clause to include broader healthcare and diagnostics activities.
The resignation of two non-executive directors and appointment of two new directors indicates board composition changes. The re-appointment of the CEO provides continuity in leadership. The dividend recommendation and investment in subsidiary signal positive shareholder returns and expansion plans.